Literature DB >> 7500017

Activation of virus replication after vaccination of HIV-1-infected individuals.

S I Staprans1, B L Hamilton, S E Follansbee, T Elbeik, P Barbosa, R M Grant, M B Feinberg.   

Abstract

Little is known about the factors that govern the level of HIV-1 replication in infected individuals. Recent studies (using potent antiviral drugs) of the kinetics of HIV-1 replication in vivo have demonstrated that steady-state levels of viremia are sustained by continuous rounds of de novo infection and the associated rapid turnover of CD4+ T lymphocytes. However, no information is available concerning the biologic variables that determine the size of the pool of T cells that are susceptible to virus infection or the amount of virus produced from infected cells. Furthermore, it is not known whether all CD4+ T lymphocytes are equally susceptible to HIV-1 infection at a given time or whether the infection is focused on cells of a particular state of activation or antigenic specificity. Although HIV-1 replication in culture is known to be greatly facilitated by T cell activation, the ability of specific antigenic stimulation to augment HIV-1 replication in vivo has not been studied. We sought to determine whether vaccination of HIV-1-infected adults leads to activation of virus replication and the targeting of vaccine antigen-responsive T cells for virus infection and destruction. Should T cell activation resulting from exposure to environmental antigens prove to be an important determinant of the steady-state levels of HIV-1 replication in vivo and lead to the preferential loss of specific populations of CD4+ T lymphocytes, it would have significant implications for our understanding of and therapeutic strategies for HIV-1 disease. To begin to address these issues, HIV-1-infected individuals and uninfected controls were studied by measurement of immune responses to influenza antigens and quantitation of virion-associated plasma HIV-1 RNA levels at baseline and at intervals after immunization with the trivalent influenza vaccine. Influenza vaccination resulted in readily demonstrable but transient increases in plasma HIV-1 RNA levels, indicative of activation of viral replication, in HIV-1-infected individuals with preserved ability to immunologically respond to vaccine antigens. Activation of HIV-1 replication by vaccination was more often seen and of greater magnitude in individuals who displayed a T cell proliferative response to vaccine antigens at baseline and in those who mounted a significant serologic response after vaccination. The fold increase in viremia, as well as the rates of increase of HIV-1 in plasma after vaccination and rates of viral decline after peak viremia, were higher in individuals with higher CD4+ T cell counts.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7500017      PMCID: PMC2192265          DOI: 10.1084/jem.182.6.1727

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  46 in total

1.  Quantitative competitive polymerase chain reaction for accurate quantitation of HIV DNA and RNA species.

Authors:  M Piatak; K C Luk; B Williams; J D Lifson
Journal:  Biotechniques       Date:  1993-01       Impact factor: 1.993

2.  Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection.

Authors:  J W Pape; S S Jean; J L Ho; A Hafner; W D Johnson
Journal:  Lancet       Date:  1993-07-31       Impact factor: 79.321

Review 3.  Multifactorial nature of human immunodeficiency virus disease: implications for therapy.

Authors:  A S Fauci
Journal:  Science       Date:  1993-11-12       Impact factor: 47.728

4.  High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR.

Authors:  M Piatak; M S Saag; L C Yang; S J Clark; J C Kappes; K C Luk; B H Hahn; G M Shaw; J D Lifson
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

5.  Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS.

Authors:  J Embretson; M Zupancic; J L Ribas; A Burke; P Racz; K Tenner-Racz; A T Haase
Journal:  Nature       Date:  1993-03-25       Impact factor: 49.962

6.  Influenza and pneumococcal vaccination of HIV-infected patients: a policy analysis.

Authors:  D N Rose; C B Schechter; H S Sacks
Journal:  Am J Med       Date:  1993-02       Impact factor: 4.965

Review 7.  Preventive health care for adults with HIV infection.

Authors:  J F Jewett; F M Hecht
Journal:  JAMA       Date:  1993-03-03       Impact factor: 56.272

8.  HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease.

Authors:  G Pantaleo; C Graziosi; J F Demarest; L Butini; M Montroni; C H Fox; J M Orenstein; D P Kotler; A S Fauci
Journal:  Nature       Date:  1993-03-25       Impact factor: 49.962

9.  Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes.

Authors:  F P Kroon; J T van Dissel; J C de Jong; R van Furth
Journal:  AIDS       Date:  1994-04       Impact factor: 4.177

10.  Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination.

Authors:  W A O'Brien; K Grovit-Ferbas; A Namazi; S Ovcak-Derzic; H J Wang; J Park; C Yeramian; S H Mao; J A Zack
Journal:  Blood       Date:  1995-08-01       Impact factor: 22.113

View more
  71 in total

1.  Antigen-driven CD4+ T cell and HIV-1 dynamics: residual viral replication under highly active antiretroviral therapy.

Authors:  N M Ferguson; F deWolf; A C Ghani; C Fraser; C A Donnelly; P Reiss; J M Lange; S A Danner; G P Garnett; J Goudsmit; R M Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

2.  Simian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection.

Authors:  S I Staprans; P J Dailey; A Rosenthal; C Horton; R M Grant; N Lerche; M B Feinberg
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

3.  Expression of MHC class II in T cells is associated with increased HIV-1 expression.

Authors:  M Saifuddin; G T Spear; C Chang; K A Roebuck
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

4.  Phosphorus and bacterial growth in drinking water.

Authors:  I T Miettinen; T Vartiainen; P J Martikainen
Journal:  Appl Environ Microbiol       Date:  1997-08       Impact factor: 4.792

5.  Identifying the target cell in primary simian immunodeficiency virus (SIV) infection: highly activated memory CD4(+) T cells are rapidly eliminated in early SIV infection in vivo.

Authors:  R S Veazey; I C Tham; K G Mansfield; M DeMaria; A E Forand; D E Shvetz; L V Chalifoux; P K Sehgal; A A Lackner
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

6.  Studies of AIDS vaccination using an ex vivo feline immunodeficiency virus model: protection conferred by a fixed-cell vaccine against cell-free and cell-associated challenge differs in duration and is not easily boosted.

Authors:  D Matteucci; M Pistello; P Mazzetti; S Giannecchini; D Del Mauro; I Lonetti; L Zaccaro; C Pollera; S Specter; M Bendinelli
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

7.  Mutational analysis of human immunodeficiency virus type 1 (HIV-1) accessory genes: requirement of a site in the nef gene for HIV-1 replication in activated CD4+ T cells in vitro and in vivo.

Authors:  Y Kawano; Y Tanaka; N Misawa; R Tanaka; J I Kira; T Kimura; M Fukushi; K Sano; T Goto; M Nakai; T Kobayashi; N Yamamoto; Y Koyanagi
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

Review 8.  The role of antigenic stimulation and cytotoxic T cell activity in regulating the long-term immunopathogenesis of HIV: mechanisms and clinical implications.

Authors:  C Fraser; N M Ferguson; F de Wolf; R M Anderson
Journal:  Proc Biol Sci       Date:  2001-10-22       Impact factor: 5.349

9.  Antigenic stimulation specifically reactivates the replication of archived simian immunodeficiency virus genomes in chronically infected macaques.

Authors:  Céline Renoux; Simon Wain-Hobson; Bruno Hurtrel; Rémi Cheynier
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 protease inhibitors block toll-like receptor 2 (TLR2)- and TLR4-Induced NF-kappaB activation.

Authors:  Ozlem Equils; Alan Shapiro; Zeynep Madak; Chunren Liu; Daning Lu
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.